Skip to main content

CRSP

Stock

CRSP

Stock
Health Care
Biotechnology

Performance overview

CRSP Price
Price Chart

Forward-looking statistics

Beta
1.34
Risk
55.47%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Crispr Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Company info

SectorHealth Care
IndustryBiotechnology
Employees355
Market cap$4.9B

Fundamentals

Enterprise value$2.6B
Revenue$37.7M
Revenue per employee—
Profit margin-215.00%
Debt to equity11.99

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$4.49
Dividend per share—
Revenue per share$0.44
Avg trading volume (30 day)$173M
Avg trading volume (10 day)$236M
Put-call ratio—

Macro factor sensitivity

Growth+6.5
Credit+2.8
Liquidity-3.6
Inflation+1.9
Commodities+3.2
Interest Rates-1.9

Valuation

Dividend yield0.00%
PEG Ratio-10.35
Price to sales119.59
P/E Ratio-10.35
Enterprise Value to Revenue68.08
Price to book2.46

Upcoming events

Next earnings dayMay 7, 2025
Next dividend day—
Ex. dividend day—

News

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Investment Research (July 11, 2025)
These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results

CRISPR Therapeutics AG CRSP posted a loss for the first quarter on Tuesday.

Benzinga (May 7, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free